Css LLC Il Decreases Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Css LLC Il trimmed its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 45.0% during the fourth quarter, Holdings Channel reports. The fund owned 550 shares of the pharmaceutical company’s stock after selling 450 shares during the quarter. Css LLC Il’s holdings in Vertex Pharmaceuticals were worth $221,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Mpwm Advisory Solutions LLC acquired a new stake in Vertex Pharmaceuticals during the 4th quarter valued at approximately $40,000. Lantern Wealth Advisors LLC grew its position in shares of Vertex Pharmaceuticals by 72.2% during the fourth quarter. Lantern Wealth Advisors LLC now owns 1,550 shares of the pharmaceutical company’s stock worth $624,000 after buying an additional 650 shares in the last quarter. Waverly Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 632.5% in the fourth quarter. Waverly Advisors LLC now owns 3,948 shares of the pharmaceutical company’s stock worth $1,590,000 after buying an additional 3,409 shares during the last quarter. Woodline Partners LP raised its holdings in Vertex Pharmaceuticals by 12.5% in the fourth quarter. Woodline Partners LP now owns 149,418 shares of the pharmaceutical company’s stock valued at $60,171,000 after acquiring an additional 16,653 shares in the last quarter. Finally, Vident Advisory LLC boosted its stake in Vertex Pharmaceuticals by 137.3% during the 4th quarter. Vident Advisory LLC now owns 19,834 shares of the pharmaceutical company’s stock valued at $7,987,000 after acquiring an additional 11,476 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 530 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $475.34, for a total value of $251,930.20. Following the sale, the executive vice president now directly owns 58,539 shares in the company, valued at approximately $27,825,928.26. The trade was a 0.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the transaction, the executive vice president now owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. This trade represents a 10.86% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,813 shares of company stock worth $1,889,514 over the last ninety days. Company insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the subject of several research analyst reports. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and boosted their target price for the stock from $408.00 to $424.00 in a research report on Tuesday, February 11th. Truist Financial upped their price objective on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Scotiabank decreased their target price on Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating for the company in a research report on Tuesday, May 6th. BMO Capital Markets set a $545.00 price target on Vertex Pharmaceuticals in a research report on Friday, January 31st. Finally, Morgan Stanley lifted their price objective on shares of Vertex Pharmaceuticals from $462.00 to $464.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 6th. Thirteen equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $515.04.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $434.03 on Friday. The stock has a market cap of $111.46 billion, a P/E ratio of -197.29, a P/E/G ratio of 2.11 and a beta of 0.51. The firm’s 50-day simple moving average is $477.78 and its 200 day simple moving average is $463.56. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $4.76 earnings per share. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.